Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Liabilities and Shareholders Equity: 2017-2018

Historic Liabilities and Shareholders Equity for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to $39.2 million.

  • Astria Therapeutics' Liabilities and Shareholders Equity fell 1.94% to $43.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $186.0 million, marking a year-over-year increase of 41.22%. This contributed to the annual value of $39.2 million for FY2018, which is 118.86% up from last year.
  • Astria Therapeutics' Liabilities and Shareholders Equity amounted to $39.2 million in FY2018, which was up 118.86% from $17.9 million recorded in FY2017.
  • In the past 5 years, Astria Therapeutics' Liabilities and Shareholders Equity ranged from a high of $39.2 million in FY2018 and a low of $17.9 million during FY2017.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $28.5 million (2017), whereas its average is $28.5 million.
  • Data for Astria Therapeutics' Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 118.86% (in 2018) over the last 5 years.
  • Astria Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $17.9 million in 2017, then surged by 118.86% to $39.2 million in 2018.